News Summary: Pfizer painkiller patent extended

Published



PATENT WIN: Drugmaker Pfizer gets an 18-month extension on a key patent for its blockbuster anti-inflammatory painkiller, as the federal government grants a new patent for Celebrex. It replaces a patent invalidated by a federal appeals court due to technical deficiencies.

THE IMPACT: The new patent for Celebrex, Pfizer’s fifth-best-selling drug, runs till December 2015. The additional time could bring Pfizer a few billion in extra revenue.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.